Literature DB >> 8624779

Evidence that implicates the parathyroid hormone-related peptide in vascular stenosis. Increased gene expression in the intima of injured carotid arteries and human restenotic coronary lesions.

S Ozeki1, A Ohtsuru, S Seto, S Takeshita, H Yano, T Nakayama, M Ito, T Yokota, M Nobuyoshi, G V Segre, S Yamashita, K Yano.   

Abstract

Proliferation of vascular smooth muscle cells (VSMCs) is considered to be one key event underlying the pathophysiology of restenosis after angioplasty. The parathyroid hormone-related peptide (PTHrP) and its receptor, a local autocrine and paracrine regulator of cellular growth in a variety of normal cell types, have been reported in the vicinity of VSMCs. To investigate how PTHrP might be involved in the process of neointimal formation after balloon angioplasty, we examined PTHrP expression in balloon-denuded rat carotid arteries and human coronary arteries that had been retrieved by directional atherectomy. In rat carotid arteries, the RNase protection assay and in situ hybridization demonstrated that PTHrP mRNA expression increased fourfold to sixfold 1 to 7 days after denudation and continued for 28 days, coincident with downregulation of PTH/PTHrP receptor mRNA expression. In situ hybridization and immunohistochemistry revealed that PTHrP expression in balloon-denuded carotid arteries was mainly localized to the neointima. To confirm the involvement of the PTHrP in human coronary artery restenotic lesions, immunohistochemical analysis of human coronary atherectomy specimens (23 primary and 10 restenotic lesions) was then performed. The number of intimal cells that expressed PTHrP protein was significantly higher in restenotic (407 +/- 53 cells/mm2; range, 143 to 739) than in stable angina (50 +/- 12 cells/mm2; range, 18 to 132; P<.05) or unstable angina (129 +/- 16 cells/mm2; range, 21 to 232; P<.05) specimens. These data demonstrate that PTHrP gene expression in VSMCs markedly increases during neointimal formation, supporting the hypothesis that PTHrP may play an important role in vascular stenosis as a regulator of VSMC proliferation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8624779     DOI: 10.1161/01.atv.16.4.565

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  5 in total

1.  Reduced coronary flow reserve in patients with primary hyperparathyroidism: a study by G-SPECT myocardial perfusion imaging.

Authors:  Cecilia Marini; Massimo Giusti; Riccardo Armonino; Giorgio Ghigliotti; GianPaolo Bezante; Lara Vera; Silvia Morbelli; Elena Pomposelli; Michela Massollo; Patrizia Gandolfo; Francesco Minuto; Gianmario Sambuceti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-04       Impact factor: 9.236

2.  EBP50 inhibits the anti-mitogenic action of the parathyroid hormone type 1 receptor in vascular smooth muscle cells.

Authors:  Gyun Jee Song; Stacey Barrick; Kristen L Leslie; Brian Sicari; Nathalie M Fiaschi-Taesch; Alessandro Bisello
Journal:  J Mol Cell Cardiol       Date:  2010-09-16       Impact factor: 5.000

3.  Opposing mitogenic and anti-mitogenic actions of parathyroid hormone-related protein in vascular smooth muscle cells: a critical role for nuclear targeting.

Authors:  T Massfelder; P Dann; T L Wu; R Vasavada; J J Helwig; A F Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

Review 4.  Parathyroid hormone-related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets.

Authors:  T L Clemens; S Cormier; A Eichinger; K Endlich; N Fiaschi-Taesch; E Fischer; P A Friedman; A C Karaplis; T Massfelder; J Rossert; K D Schlüter; C Silve; A F Stewart; K Takane; J J Helwig
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

5.  Endogenous parathyroid hormone-related protein regulates the expression of PTH type 1 receptor and proliferation of vascular smooth muscle cells.

Authors:  Gyun Jee Song; Nathalie Fiaschi-Taesch; Alessandro Bisello
Journal:  Mol Endocrinol       Date:  2009-07-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.